Search Result

Results for "

741

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Androgen Receptor (1) Antibiotic (3) Bacterial (3) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) Dopamine Receptor (1) Drug Metabolite (1) Estrogen Receptor/ERR (1) Histone Methyltransferase (1) iGluR (1) Integrin (4) Interleukin Related (1) mAChR (1) MicroRNA (16) Phospholipase (4) PKC (1) Ser/Thr Protease (1) SHP2 (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Endocrinology (1) Infection (4) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	miRNA mimics (4) miRNA agomirs (4) miRNA antagomirs (4) MicroRNAs (16) miRNA inhibitors (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1649B

SPR741 acetate 3 Publications Verification NAB741 acetate	Bacterial Antibiotic	Infection
SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 acetate inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 acetate .

HY-P1649

SPR741 3 Publications Verification NAB741	Bacterial Antibiotic	Infection
SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 .

HY-19151

Fuzapladib IS-741	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-19151A

Fuzapladib sodium IS-741 sodium	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-P1649A

SPR741 TFA NAB741 TFA	Bacterial Antibiotic	Infection
SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 TFA inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA .

HY-107644

AQ-RA 741	mAChR	Cardiovascular Disease
AQ-RA 741 is a potent and selective M 2 antagonist. AQ-RA 741 inhibits the vagally or agonist-induced bradycardia in rats, cats and guinea-pigs. AQ-RA 741 is used in bradycardiac disorders research .

HY-111544

EML741	Histone Methyltransferase	Cancer
EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC₅₀ of 23 nM, K_d of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC₅₀, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated .

HY-19151B

Fuzapladib potassium IS-741 potassium	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-R04025

*mmu-miR-741-3p mimic*	MicroRNA	Cancer
mmu-miR-741-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-741-3p mimic mmu-miR-741-3p mimic

HY-R04026

*mmu-miR-741-5p mimic*	MicroRNA	Cancer
mmu-miR-741-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-741-5p mimic mmu-miR-741-5p mimic

HY-R04568

*rno-miR-741-5p mimic*	MicroRNA	Cancer
rno-miR-741-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-741-5p mimic rno-miR-741-5p mimic

HY-R04567

*rno-miR-741-3p mimic*	MicroRNA	Cancer
rno-miR-741-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-741-3p mimic rno-miR-741-3p mimic

HY-RI04025

*mmu-miR-741-3p inhibitor*	MicroRNA	Cancer
mmu-miR-741-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-741-3p inhibitor mmu-miR-741-3p inhibitor

HY-RI04568

*rno-miR-741-5p inhibitor*	MicroRNA	Cancer
rno-miR-741-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-741-5p inhibitor rno-miR-741-5p inhibitor

HY-RI04026

*mmu-miR-741-5p inhibitor*	MicroRNA	Cancer
mmu-miR-741-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-741-5p inhibitor mmu-miR-741-5p inhibitor

HY-RI04567

*rno-miR-741-3p inhibitor*	MicroRNA	Cancer
rno-miR-741-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-741-3p inhibitor rno-miR-741-3p inhibitor

HY-R04026A

*mmu-miR-741-5p agomir*	MicroRNA	Cancer
mmu-miR-741-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-741-5p agomir mmu-miR-741-5p agomir

HY-R04567A

*rno-miR-741-3p agomir*	MicroRNA	Cancer
rno-miR-741-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-741-3p agomir rno-miR-741-3p agomir

HY-R04568A

*rno-miR-741-5p agomir*	MicroRNA	Cancer
rno-miR-741-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-741-5p agomir rno-miR-741-5p agomir

HY-R04025A

*mmu-miR-741-3p agomir*	MicroRNA	Cancer
mmu-miR-741-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-741-3p agomir mmu-miR-741-3p agomir

HY-RI04025A

*mmu-miR-741-3p antagomir*	MicroRNA	Cancer
mmu-miR-741-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-741-3p antagomir mmu-miR-741-3p antagomir

HY-RI04567A

*rno-miR-741-3p antagomir*	MicroRNA	Cancer
rno-miR-741-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-741-3p antagomir rno-miR-741-3p antagomir

HY-RI04026A

*mmu-miR-741-5p antagomir*	MicroRNA	Cancer
mmu-miR-741-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-741-5p antagomir mmu-miR-741-5p antagomir

HY-RI04568A

*rno-miR-741-5p antagomir*	MicroRNA	Cancer
rno-miR-741-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-741-5p antagomir rno-miR-741-5p antagomir

HY-101261

ATPA	iGluR	Neurological Disease
ATPA is a selective glutamate receptor GluR5 activator with EC₅₀s of 0.66, 9.5, 1.4, 23, 32, 18, and 14 μM for GluR5wt, GluR5(S741M), GluR5(S721T), GluR5(S721T, S741M), GluR5(S741A), GluR5(S741L), and GluR5(S741V), respectively .

HY-134932

AA74-1	Ser/Thr Protease	Inflammation/Immunology
AA74-1 is a potent and selective inhibitor of APEH. AA74-1 significantly increases T cells proliferation by blocking the APEH activity .

HY-19151C

Fuzapladib calcium IS-741 calcium	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-P990220

Anti-Mouse IL-18 Antibody (YIGIF74-1G7) 1 Publications Verification	Interleukin Related	Infection Inflammation/Immunology Cancer
Anti-Mouse IL-18 Antibody (YIGIF74-1G7) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IL-18. Anti-Mouse IL-18 Antibody (YIGIF74-1G7) can neutralize IL-18. Anti-Mouse IL-18 Antibody (YIGIF74-1G7) can be used for the researches of cancer, infection, inflammation and immunology, such as hepatocellular carcinoma and eosinophilic esophagitis .

HY-155349

AChE/BuChE-IN-4	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-4(compound 4a) is aorally activeandbrain-penetrantmultitarget-directedAChE/BuChEinhibitor againstAChEandBuChE, with theIC₅₀of 2.08 and 7.41 μM .

HY-136242

UT-34	Estrogen Receptor/ERR	Endocrinology Cancer
UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC₅₀ values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and *W741L-AR*, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects.

HY-139466

PF-03622905	SHP2 PKC	Metabolic Disease
PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC₅₀s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases .

HY-145889

LC kinetic stabilizer-1	Biochemical Assay Reagents	Others
LC kinetic stabilizer-1 (compound 21) is a potent and selective amyloidogenic immunoglobulin light chain kinetic stabilizer with EC₅₀s of 140 and 74.1 nM for WIL-FL ^* and WIL-FL ^* T46L/F49Y, respectively. WIL-FL is an amyloidogenic FL LC dimer .

HY-12709A

ARC 239 dihydrochloride	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pK_d values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHO cell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pK_is of 5.6, 8.4, and 7.08, respectively .

HY-W587772

Mono(2-ethyl-5-hydroxyhexyl) terephthalate MEHHTP	Drug Metabolite	Metabolic Disease
Mono (2-ethyl-5-hydroxyhexyl) terephthalate (MEHHTP), a hydroxyl metabolite of the phthalate alternative Di-2-ethylhexyl terephthalate (DEHTP), is a liver X receptor α (LXRα) agonist with a binding energy of -7.41 kcal/mol. Mono (2-ethyl-5-hydroxyhexyl) terephthalate upregulates LXRα downstream targets such as SREBP-1c and FASN and increases lipogenic enzyme activity in hepatocytes, and elevating triglyceride (TG) levels. Mono (2-ethyl-5-hydroxyhexyl) terephthalate is promising for research of nonalcoholic fatty liver disease (NAFLD) .

HY-100539

PD 128907	Dopamine Receptor	Others
PD 128907 is a D3 receptor ligand with activities of activating dopamine receptors, inhibiting cell firing, and inhibiting dopamine release. The active (+) enantiomer of PD 128907 has high affinity and selectivity for rat D3 dopamine receptors. PD 128907 inhibits cell firing in the ventral tegmental area and substantia nigra pars compacta with EC₅₀ values of 33nM and 38nM, respectively. PD 128907 also inhibits dopamine release in the caudate putamen with an EC₅₀ of 66nM. However, the selective D2 receptor antagonist L-741,626 has high affinity for receptors activated by PD 128907, indicating that the effects of PD 128907 are more likely on D2 autoreceptors rather than D3 dopamine receptor subtypes.

HY-159922

AR antagonist 9	Androgen Receptor	Cancer
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC₅₀ value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC₅₀ = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against AR_F876L/T877A and *AR_W741C* mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .

Cat. No.	Product Name	Target	Research Area